Gerald Swiss es socio jubilado y abogado especializado en propiedad intelectual de Foley & Lardner LLP. Centró su práctica en el asesoramiento estratégico, incluida la implementación de estrategias de propiedad intelectual para clientes en los ámbitos biofarmacéutico, de las ciencias de la vida y de los dispositivos médicos. Gerald cuenta con aproximadamente 35 años de experiencia en propiedad intelectual en la tramitación de patentes destinadas a proteger moléculas pequeñas, procesos químicos, enzimas y dispositivos médicos. En particular, ha gestionado una importante cantidad de trabajo de propiedad intelectual sobre nuevos andamios de entidades químicas para el tratamiento de cánceres, anemia, trombosis y enfermedades inflamatorias. Fue miembro del departamento de Química, Biotecnología y Farmacia de la firma.
In addition to his patent prosecution skills, Gerald’ legal experience included developing international patent strategies for critical lead compounds and new discovery platforms, addressing due diligence, freedom to operate, validity and infringement/non-infringement analyses, as well as patent procurement.
Gerald started his career as a medicinal research chemist at Schering Corporation, where he worked in the synthesis of small molecules in the pharmaceutical arena. His research focused on anti-inflammatory and anti-hypertensive compounds.
Premios y reconocimientos
In recognition of his experience, he has been Peer Review Rated as AV® Preeminent™, the highest performance rating in Martindale-Hubbell’s peer review rating system. He has been selected for inclusion in The Best Lawyers in America® since 2012 and The Legal 500 also recognized Gerald in 2011 and 2013 as one of the leading lawyers in the U.S. for patent prosecution: utility and design patents. He was also recognized among IAM Patent 1000 – The World’s Leading Patent Practitioners (2012-2016). In 2015, Gerald was named an IP Star by Managing Intellectual Property magazine. Past clients have noted his writing skills and strategic counseling, both of which have made Gerald highly sought-after by pharmaceutical companies.